Aires Research Timeline: 1992 to 2025

Foundation Era (1992–2001)

1992 — Founding and Initial Research

The Aires Human Genome Research Foundation is established in St. Petersburg, Russia. Inventor Igor Serov begins developing the concept of coherent EMF transformation via self-affine fractal geometry.

1996–2000 — First EMF Measurements

Early RF range resonator experiments characterize intrinsic frequency behavior across 1–40 GHz.

2000 — Russian Ministry of Health Protocol Approval

The Russian Ministry of Health approves an official clinical trial protocol for the Aires Matrix Applicator. Protocol documentation ›

2000 — Army Medical Academy Clinical Trial

St. Petersburg Army Medical Academy conducts clinical trials of the Aires Matrix Applicator in 21 subjects with psychoemotional stress. EEG, HRV, cognitive and neuromotor tests all show significant improvement. Read the study ›

2001–2002 — Bekhterev Institute EEG Research

V.M. Bekhterev National Medical Research Center conducts EEG research on Aires Optical Fractal Matrix Filters in 54 patients with anxious asthenic syndrome. Read the study ›

Expansion Era (2002–2010)

2002 — Zenin Water Conductivity Study

Dr. Stanislav Zenin (Ministry of Health, Russia) documents that radiotelephone EMF measurably alters water electrical conductivity. The Aires Neutralizer provides complete compensation. Read the study ›

2003 — Rybina & Alexandrov: EEG "Electromagnetic Storm" Discovery

Larisa Rybina and Boris Alexandrov (Pavlov Institute) document that mobile phone use creates what they term an "electromagnetic storm" in EEG brain patterns. Aires Shield reduces the disruption. Read the study ›

2003 — Comparative EEG Study (7 Devices)

Rybina compares Aires NEMA against 6 competing protective devices. Aires outperforms all alternatives on all EEG measures. Read the study ›

2005 — Tarlykov Erythrocyte Study (ITMO)

Prof. Vladimir Tarlykov at ITMO University demonstrates that the Aires Fractal Resonator improves erythrocyte deformability in blood from multiple myeloma patients. Read the study ›

Systematic Validation Era (2013–2018)

2013 — Datova HRV Study

Svetlana Datova (Tyumen State University) conducts 13-subject placebo-controlled HRV study. Aires Defender significantly improves heart rate variability and autonomic regulation. Read the study ›

2014 — Sysoev & Serov EEG Study (GSM-900)

Prof. Sysoev (Military Medical Academy) and Serov conduct 11-subject EEG study. Aires Shield eliminates mobile phone-induced theta/alpha elevation on the phone-side brain hemisphere. Read the study ›

2015 — Havas (Trent University) Cardiovascular Studies

Dr. Magda Havas at Trent University, Canada, publishes two independent placebo-controlled case studies. First international (non-Russian) research institution to study Aires. Read the studies ›

2016 — VGTU Phase I: Spectrum Analyzer Measurement

Prof. Jukna and Dr. Jasaitis at VGTU (Lithuania) conduct Phase I independent testing. Result: 27% average reduction in electric field strength across 0.9–2.5 GHz. Read the study ›

2016 — IFRAN Stage 1: Chromosome Aberration Discovery

Dyuzhikova et al. at Pavlov Institute document that Wi-Fi router exposure causes 4.5× increase in chromosome aberrations in rat bone marrow. Aires Defender reduces aberrations 4-fold. Read Stage 1 ›

2017 — IFRAN Stages 2 & 3: DNA and Memory Effects

Stage 2 confirms DNA damage across multiple rat genetic lines. Stage 3 documents Wi-Fi-induced memory impairment and its restoration by Aires resonators. Stages 2 & 3 ›

2017–2018 — VGTU Phases II & III: Interference Mechanism Confirmed

Follow-up VGTU testing confirms interference mechanism (20% field amplitude reduction). Read Phases II & III ›

2018 — ITMS Peer-Reviewed Publication (VGTU + ITMO)

Joint publication by Jukna/Jasaitis (VGTU) and Lukyanov/Kopyltsov (ITMO) in ITMS 2018 proceedings. Read the ITMS paper ›

2018 — IFRAN Stage 4: Magnetic Field Effects

Reduced magnetic field disrupts behavior in HT and LT rat lines; Aires Defender Pro normalizes effects. Stage 4 ›

Advanced Validation Era (2019–2025)

2019 — Patent Filed (WO2021/064446)

WIPO global patent application filed covering the method for transforming technogenic EMF into coherent radiation via self-affine fractal resonator.

2019 — IFRAN Stage 5: Locomotion, Bees, hsp70 Gene

Stage 5: (a) locomotion effects in LT rats normalized by Aires Defender Pro; (b) Wi-Fi router suppresses hsp70 gene expression in honey bee brain; Aires Defender Pro restores it. Stage 5 ›

2020 — Rybina EEG Study (15 Subjects)

Rybina conducts rigorous 15-subject EEG study documenting mobile phone EMF disruption and Aires Resonator restoration. Read the study ›

2020 — Kuznetsova ECG/HRV Study (15 Subjects)

Aires Shield Pro reduces regulatory stress index by 2× during mobile phone exposure. Read the study ›

2022 — Springer Publication (ICICT 2022)

Lukyanov, Kopyltsov & Serov publish peer-reviewed computer simulation in Springer Lecture Notes in Networks and Systems. Read the Springer paper ›

2025 — US Patent Granted (US12239835B2)

US Patent US12239835B2 granted March 4, 2025. Covers coherent EMF transformation via self-affine fractal resonator across 2.4 GHz through 28 GHz. Expires December 13, 2040. Patent documentation ›

2025 — Pavlov Institute: First Wi-Fi 6 and First Genotype-Dependent Response

Most recent study. Pavlov Institute tests Lifetune Zone Max against Wi-Fi 6 router on rats. Key findings: (1) Wi-Fi 6 router measurably alters blood parameters; (2) Lifetune Zone Max normalizes them; (3) first genotype-dependent variation in EMF response documented. Read the 2025 study ›

2026 — ICICT 2026 Thermal Imaging Confirmation

Lukyanov & Makarov use thermal imaging to physically confirm that the Aires resonator self-affine surface behaves as a near-black-body electromagnetic cavity. Published at Springer ICICT 2026. Read the thermal imaging study ›

What This Timeline Demonstrates

The research arc is not a collection of isolated studies — it is a sustained, cumulative scientific program with five clear properties:

1. Chronological continuity (33 years): Research did not start when the company needed marketing. It started at the founding and has continued without interruption.
2. Methodological escalation: Early descriptive studies gave way to placebo-controlled designs, multi-stage longitudinal programs, and peer-reviewed publications.
3. Geographic expansion: Research that began exclusively in Russia expanded to Canada (Trent, 2015), Lithuania (VGTU, 2016–2018), and the US (UFC Performance Institute).
4. Convergent validation: Physical mechanism (simulation, thermal imaging, spectrum analysis) and biological outcomes (EEG, HRV, genetics, blood) converge on the same conclusion independently.
5. Current-technology validation: The 2025 IFRAN study and 2026 ICICT publication are the most recent additions — the research program continues to match evolving wireless technology.